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Abstract
Introduction: Pendred syndrome, a combination of sensorineural deafness, impaired organiﬁcation of
iodide in the thyroid and goitre, results from biallelic defects in pendrin (encoded by SLC26A4), which
transports chloride and iodide in the inner ear and thyroid respectively. Recently, pendrin has also been
identiﬁed in the kidneys, where it is found in the apical plasma membrane of non-a-type intercalated
cells of the cortical collecting duct. Here, it functions as a chloride–bicarbonate exchanger, capable of
secreting bicarbonate into the urine. Despite this function, patients with Pendred syndrome have not
been reported to develop any signiﬁcant acid–base disturbances, except a single previous reported case
of metabolic alkalosis in the context of Pendred syndrome in a child started on a diuretic.
Case report: We describe a 46-year-old female with sensorineural deafness and hypothyroidism, who
presented with severe hypokalaemic metabolic alkalosis during inter-current illnesses on two
occasions, and who was found to be homozygous for a loss-of-function mutation (V138F) in SLC26A4.
Her acid–base status and electrolytes were unremarkable when she was well.
Conclusion: This case illustrates that, although pendrin is not usually required to maintain acid–base
homeostasis under ambient condition, loss of renal bicarbonate excretion by pendrin during a
metabolic alkalotic challenge may contribute to life-threatening acid–base disturbances in patients
with Pendred syndrome.
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Introduction
First reported in 1896 (1), Pendred syndrome is an
autosomal recessive disorder due to biallelic mutations
in SLC26A4 (2). This gene encodes pendrin, a member
of the SLC26 family of multi-functional membrane-
spanning anion transporters. Pendrin was initially
shown to be expressed in the inner ear and thyroid. In
the cochlea, it acts as a chloride/bicarbonate exchanger,
where it contributes to endolymph homeostasis,
whereas in the thyroid, it mediates iodide transport at
the apical membrane of thyrocytes (3) (Fig. 1). Recently,
pendrin has also been identiﬁed in the kidney (4, 5).
Here, it localises to the apical plasma membrane of
non-a-type intercalated cells of the cortical collecting
duct, where it functions as a chloride–bicarbonate
exchanger, secreting bicarbonate into the luminal ﬂuid
in alkalotic states. However, the exact physiological role
of renal pendrin in humans has remained uncertain.
In this study, we describe a woman with Pendred
syndrome that was only recognised after two episodes of
life-threatening metabolic alkalosis. Our case illustrates
that, although not required under normal conditions,
pendrin expressed in the kidney does play a critical role
in humans in protecting against metabolic alkalosis.
Case report
A 46-year-old Caucasian female was admitted to
hospital after being found on the ﬂoor of her home,
confused and with rigid limbs. The medical history
elicited from her family included childhood-onset
sensorineural hearing loss and mild hypothyroidism
that had been diagnosed at the time of cochlear
implantation 1 year earlier. There was a long history
of alcohol excess. Her only medication was levothyrox-
ine 50 mg daily. Initial examination revealed a small
goitre, a sinus tachycardia (120 beats/min) and reduced
oxygen saturation (91% on air). Tone in all limbs was
increased with bilateral carpal spasms and rightward
tonic deviation of the neck.
Initial arterial blood gas measurements indicated
a severe metabolic alkalosis with hypoventilation:
pH 7.59, pO2 7.08 kPa, pCO2 6.39 kPa, bicarbonate
(HCO3) 45 mmol/l and base excess C20.4 (normal
ranges 7.36–7.44; 9.3–13.3 kPa; 4.5–6.0 kPa;
22–26 mmol/l and K2t oC2 respectively). Venous
biochemistry (Table 1) showed severe hypokalaemia
and hypochloraemia. In addition, her deranged liver
function tests, low platelets, severe hypomagnesaemia
and raised mean cell volume (MCV) (Table 1) were
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Inﬂammatory markers and lactate level were elevated,
suggestive of infection. Her thyroid function tests
(Table 1) were indicative of either under-replacement
or non-compliance.
Central venous access was obtained for ﬂuid and
electrolyte resuscitation, with close monitoring of ﬂuid
balance. She desaturated and developed a severe
respiratory acidosis 24 h after admission, culminating
in respiratory arrest that required intubation and
ventilation. In the ICU, she received a continuous
infusion (20–30 mmol/h) of potassium with hourly
electrolyte measurement, but also required several
infusions of magnesium (each 20 mmol/2 h), together
with i.v. boluses of calcium gluconate. A ventricular
ﬁbrillation (VF) cardiac arrest responded to DC
cardioversion and i.v. amiodarone 36 h post-admission,
but she experienced several further VF arrests despite
improvements in her venous K and Mg levels.
Her electrolyte balance stabilised by day 4, but
her recovery after extubation was complicated by a
chest infection requiring antibiotic treatment. Her
potassium and calcium levels eventually normalised
without ongoing replacement. Her elevated random
blood glucose level normalised without treatment,
suggesting that this was a stress response. Oral mag-
nesium supplementation on discharge (day 37) was
discontinued 4 weeks later, after which her electrolyte
balance remained normal. Her blood pressure was
130/80 mmHg when she was well.
Review of previous charts indicated that the
patient had been hospitalised 1 year earlier, following
3 days of persistent vomiting, with similarly deranged
biochemistry. During admission, her biochemical
disturbances normalised after appropriate treatment,
without undue complications. Retrospective analysis of
investigations at that time revealed inappropriately
high urinary potassium excretion in the face of
hypokalaemia (urine K 41.3 mmol/l; serum K
1.4 mmol/l; urine osmolality 490 mOsm) and raised
fractional excretion of both magnesium and chloride
(5.8 and 4.75% respectively, normal ranges !4.0 and
!0.8%). Aldosterone levels were appropriately sup-
pressed. In particular, between the current and the
previous hospital admissions, her plasma electrolytes
had not required supplementation. Her thyroid dysfunc-
tion at the time of diagnosis of hypothyroidism in 2006
was mild (TSH 6.9 mU/l; free thyroxine 9.7 pmol/l;
reference ranges as in Table 1)a n da n t i - t h y r o i d
peroxidase antibodies were normal.
Review of inner ear imaging showed bilaterally
enlarged vestibular aqueducts (EVA; Fig. 2A) and single-
cavity cochleae (Mondini defect; Fig. 2B) (6). The combi-
nation of bilateral sensorineural hearing loss, goitrous
non-autoimmune hypothyroidism and cochlear defects
suggested a unifying diagnosis of Pendred syndrome.
SequencingofSLC26A4conﬁrmedthis,revealingthatthe
patient is homozygous for a missense valine to phenyl-
alanine mutation (V138F) in pendrin, which has
previously been described in this disorder (7).
Discussion
About 150 diverse mutations in SLC26A4, predomi-
nantly missense, have been reported in Pendred
syndrome (8). The V138F change found in our patient
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Figure 1 Cellular functions of pendrin. In the thyroid, pendrin is
involved in apical iodide transport (see ref. (3) for discussion); in
the inner ear it transports bicarbonate into endolymph in exchange
for chloride; and in renal collecting duct b-intercalated cells, it
participates in urinary bicarbonate excretion with tubular chloride
reabsorption. NIS, sodium iodide symporter; I, iodide; Cl, chloride;
HCO3, bicarbonate. Full colour version of this ﬁgure available via
http://dx.doi.org/10.1530/EJE-11-0101.
Table 1 Venous biochemical and haematological parameters at
presentation.
Results Reference range
Sodium (mmol/l) 137 135–145
Potassium (mmol/l) 1.4 3.4–5.0
Calcium (mmol/l) 2.07 2.1–2.5
Magnesium (mmol/l) 0.19 0.7–1.0
Phosphate (mmol/l) 0.62 0.8–1.4
Chloride (mmol/l) 86 95–106
Bicarbonate (mmol/l) 45 21–32
Glucose (mmol/l) 10.5 3.5–5.5
Creatinine (mmol/l) 126 35–125
Urea (mmol/l) 9.3 0–7.5
Lactate (mmol/l) 2.6 Up to 2.0
White cells (!10
9/l) 24.2 4.0–11
Neutrophils (!10
9/l) 20.69 2.0–8.0
C-reactive protein (mg/l) 81 0–6
Haemoglobin (g/dl) 15.7 11.5–16.0
MCV (ﬂ) 112.3 80–100
Platelets (!10
9/l) 91 150–400
Alanine aminotransferase (U/l) 177 0–50
Alkaline phosphatase (U/l) 141 30–135
Bilirubin (mmol/l) 51 0–17
Albumin (g/l) 32 30–35
TSH (mU/l) 6.30 0.35–5.5
Free thyroxine (pmol/l) 8.4 11.5–22.7
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of the mutant protein in the endoplasmic reticulum (9).
Failure of chloride transport in the inner ear alters
endolymphatic potential, leading to endolymphatic
hydrops manifesting as an EVA, as seen in our patient.
The late-onset hypothyroidism is attributable to defec-
tive iodide transport and organiﬁcation in the thyroid
(10). We suggest that her propensity to profound
metabolic alkalosis in particular clinical contexts is
mediated by loss of pendrin function in the kidney.
Under normal conditions, the human omnivorous
diet generates a net gain of acid of about 1 mmol H
C/kg
body weight/day, such that there is little need for renal
bicarbonate-excretory function. Instead, the kidney
usually acts to conserve bicarbonate, with 90% of
ﬁltered bicarbonate being reabsorbed in the proximal
convoluted tubule and the residual 10% in the cortical
collecting duct via the chloride–bicarbonate exchanger
AE1 (known in its red cell isoform as Band-3) at the
basolateral surface of a-intercalated cells. In contrast,
the pendrin-expressing b-intercalated cells in the
collecting duct are bicarbonate secreting, but this
function is likely to be less active in humans given our
diet, and few b-intercalated cells are observed on renal
microscopy (11). Thus, under ambient conditions,
individuals with Pendred syndrome can maintain
normal acid–base homeostasis.
However, our patient illustrates the failure of normal
compensatory mechanisms that operate during meta-
bolic alkalosis. Vomiting and alcohol excess were likely
causative factors that initially disturbed acid–base
homeostasis in our patient (12), which spiralled in a
vicious cycle resulting in severe metabolic alkalosis
because renal b-intercalated cell function could not be
up-regulated. In support of this, murine studies during
metabolic alkalosis have shown signiﬁcant up-regula-
tion of renal pendrin mediating enhanced bicarbonate
excretion in the cortical collecting duct, together with
down-regulation of proximal tubular bicarbonate
reabsorption via other transporters, as normal compen-
satory mechanisms. Furthermore, pendrin-null mice
exhibit higher serum bicarbonate levels and impaired
excretion of hydroxide equivalents following dietary
electrolyte or pharmacological manipulation (13),
conﬁrming its role in acid–base homeostasis. By
analogy, we suggest that the marked metabolic alkalosis
in our patient reﬂected failure of a similar compensatory
mechanism, with deﬁciency of pendrin in the kidney
impairing bicarbonate excretion. In addition, hypo-
kalaemia due to insufﬁcient oral intake, transient renal
tubular loss or a combination of both probably further
contributed to metabolic alkalosis byenhancing cellular
H
C ion uptake (14).
Only a single previous case of metabolic alkalosis in
the context of Pendred syndrome has been reported
(15). In that report, a child with the disorder developed
severe metabolic alkalosis and hypokalaemia, but in the
context of commencement of thiazide diuretic therapy
for endolymphatic hydrops, presumably being unable
to compensate for drug-induced renal chloride and
potassium losses, leading to alkalosis.
The severity of our patient’s metabolic abnormalities,
particularly her hypomagnesaemia and apparent resist-
ance to corrective measures, did prompt us to consider
alternative underlying predisposing causes. However,
the Gitelman/Bartter spectrum or a primary hypo-
magnesaemia was ruled out by her recovery without
long-term requirement for electrolyte supplements.
In summary, this patient’s unusual clinical pre-
sentation highlights that in the kidney, pendrin does
play a part in maintaining acid–base homeostasis in
humans, with its absence and consequent failure of
renal bicarbonate excretion leading to potentially
life-threatening metabolic alkalosis in the context of
inter-current illness.
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